Skip to main navigation Skip to search Skip to main content

In utero exposure to tenofovir disoproxil fumarate does not impair growth and bone health in HIV-uninfected children born to HIV-infected mothers

  • A Viganò
  • , S Mora
  • , V Giacomet
  • , S. Stucchi
  • , V Manfredini
  • , C Gabiano
  • , F Salvini
  • , M Cellini
  • , Enrica Tamburrini
  • , M Puzzovio
  • , Gv Zuccotti

Research output: Contribution to journalArticle

Abstract

Growth impairment and bone toxicity due to tenofovir disoproxil fumarate (TDF) fetal exposure has been described mainly in animals. We evaluated growth pattern and bone health in TDF-exposed HIV-uninfected children born to HIV-infected mothers, defined as seroreverters (SR).
Original languageEnglish
Pages (from-to)1259-1266
Number of pages8
JournalAntiviral Therapy
Volume16
DOIs
Publication statusPublished - 2011

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Adenine
  • Adult
  • Anti-HIV Agents
  • Antiretroviral Therapy, Highly Active
  • Bone and Bones
  • Child
  • Child, Preschool
  • Cohort Studies
  • Cross-Sectional Studies
  • Female
  • Fetus
  • HIV
  • HIV Infections
  • HIV Seropositivity
  • Humans
  • Infant
  • Infectious Disease Transmission, Vertical
  • Italy
  • Male
  • Observation
  • Phosphonic Acids
  • Pregnancy
  • Reverse Transcriptase Inhibitors

Fingerprint

Dive into the research topics of 'In utero exposure to tenofovir disoproxil fumarate does not impair growth and bone health in HIV-uninfected children born to HIV-infected mothers'. Together they form a unique fingerprint.

Cite this